OrbiMed has raised $3 billion to invest in biotech and life sciences companies across the U.S., Europe and Asia, with the biggest step-up coming in its Asia allocation. The firm said OrbiMed Asia Partners VI raised over $1 billion for healthcare growth equity and venture capital, making it the company’s largest Asia-focused fund and lifting the region’s share of OrbiMed’s new war chest.
The increase is notable because it comes only three years after the prior versions of these vehicles closed. OrbiMed Asia Partners VI is larger than the $751 million committed to the fifth fund and the $800 million raised for the fourth, while OrbiMed Private Investments X brought in more than $1.9 billion for U.S. and European life science venture capital opportunities, slightly above its predecessor’s $1.86 billion and well above the $1.5 billion fund raised in 2021.
Why Asia Is Getting More Capital
The Asia fund is the clearest signal in the announcement. Investor interest in Asian biotechs has been rising as the region, driven by China, becomes a major source of new drug candidates for Western pharmaceutical companies and a potential base for new global drugmakers. Earlier this month, TCGX raised $600 million for its first Asia life sciences fund and opened offices in Shanghai and Hong Kong.
OrbiMed’s positioning predates that recent acceleration. Its current portfolio includes 22 Asian biopharma companies, and Managing Partner Carl Gordon cited “China's emergence as a biotechnology powerhouse” as one reason he sees unusual opportunity in life sciences investing now. He also pointed to AI and the proliferation of therapeutic modalities as expanding the opportunity set for developing new treatments.
The broader takeaway is that capital allocators are no longer treating Asia only as a place to source licensing deals after programs mature. A larger dedicated fund aimed at healthcare growth equity and venture capital suggests investors expect company creation and scaling in the region to support direct, earlier-stage returns.
Where The Money Goes Next
Both new vehicles will invest across biopharma, medtech and technology-enabled healthcare services. That breadth matters because it shows the fundraising is not a narrow single-theme bet, even though the Asia vehicle is likely to draw the most attention.
OrbiMed also enters this cycle with recent validation from its U.S. biotech portfolio. Forte Biosciences and Crinetics Pharmaceuticals agreed to buyouts worth $2.2 billion and $10 billion, respectively, in July, and Braveheart Bio, BlossomHill Therapeutics and ADARx Pharmaceuticals all went public over the following two months.
For the market, the message is straightforward: one of healthcare’s largest specialist investors has fresh capital for three regions, but it is increasing exposure fastest where biopharma innovation is becoming more globally relevant. That does not guarantee returns, but it does show where a major allocator believes the next wave of company building is most likely to emerge.
